SELLAS Life Sciences Group reported its Q2 results on August 12 with one of the most heavily contested short positions in small-cap biotech still intact — and the data since the print shows bears have not retreated.
Short interest tells a story of stubborn conviction rather than a covering rush. At 38.2% of the free float — roughly 54.4 million shares — short interest has actually ticked up 1.2% on the week, reversing briefly after a multi-week decline from the late-July peak above 67 million shares. Days to cover remain near eight sessions, meaning any forced unwind would play out over a meaningful period. The ORTEX short score holds at 81.97, placing SLS in the 2nd percentile of the entire universe by short score rank — a reading that has been broadly stable across the past ten days, narrowing only slightly from 83.4 at the end of July.
The borrow market has loosened since the extreme levels of early summer, but it remains genuinely tight. Availability now runs at around 10.9% — roughly one share available for every nine already borrowed. That is a notable improvement from August 6, when availability nearly evaporated entirely to 0.4%, but it is still well within territory that constrains new short positioning. Cost to borrow has followed the same trajectory: it peaked near 193% annualised at the start of July and has since fallen sharply to 14.6% — still elevated in absolute terms, but less punishing for existing holders. Options positioning is unremarkable. The put/call ratio of 0.41 sits almost exactly on its 20-day average, with a z-score near zero, suggesting options traders are neither adding meaningful downside hedges nor expressing fresh bullish conviction into the print.
The Street angle for SLS is sparse in terms of recent analyst activity. The most current published action is a Maxim Group target raise to $10 from March 2026, which now sits well below the current $11.05 share price. The mean analyst price target of $32.50 implies substantial theoretical upside, but the underlying coverage base is thin, the most recent non-Maxim actions date to 2023 or earlier, and the gap between current price and consensus target should be treated with caution given the staleness of the data. What the factor scores do confirm is that short dynamics dominate this stock's character: the short score ranks in the 2nd percentile and availability ranks in the 5th percentile, while EPS surprise sits at just the 36th percentile and dividend score at the 32nd.
The earnings history adds meaningful context here. The three prior events with available reaction data show a stock that moves sharply after results: a 24% one-day gain on May 12, a 7.2% gain on May 18, and a near-flat next-day response to the June 16 print that nonetheless resolved into a 17.3% five-day move. The pattern is one of high post-earnings volatility with a bullish directional bias in recent quarters. Peer names from the correlated clinical-stage biotech cohort — including COYA, up 5% on the week, and FDMT, up 11.8% — have moved constructively over the same period that SLS has slipped 6.4%. That divergence suggests the SLS decline is stock-specific rather than a sector-wide move.
Institutional ownership adds one more layer. BlackRock added 2.9 million shares in the most recent reporting period, reaching 7.7% of the company, while State Street increased its position by 4.6 million shares to 6.6%. Vanguard established a new position of 8.7 million shares. That trio of passive and index-adjacent buyers now collectively controls nearly 19% of the company — a meaningful counterweight to the short side, even if their buying is largely driven by index mechanics rather than active conviction.
What to watch next is whether the August 12 print produces the kind of multi-day follow-through seen after prior results, or whether the partial covering that has already occurred — from 67 million shares shorted in late July down to 54 million — represents the extent of the short-side retreat, with the remaining 38% float position dug in regardless of the headline.
See the live data behind this article on ORTEX.
Open SLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
